Abstract
Over the last two decades, tremendous advances have been made in the treatment of psoriatic disease. Our understanding of the complex immunopathogenesis of this chronic inflammatory condition has led to the development of highly effective, safe, targeted monoclonal antibodies that result in clearance in the vast majority of treated patients. However, these recently approved therapies have multiple drawbacks and limitations that necessitate the development and testing of additional treatment modalities. To address this need, scientists and the pharmaceutical industry have pursued the identification and testing of several oral small molecules as novel treatments for plaque and psoriatic arthritis. These molecules in testing include JAK/TYK2 inhibitors, phosphodiesterase inhibitors, RORĪ³t inhibitors, fumarate esters, sphingosine 1 phosphate antagonists, neurokinin-1 receptor antagonists, adenosine A3 receptor agonists, H4 receptor antagonists, PRINS inhibitors, and spleen tyrosine kinase inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hawkes JE, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605ā13.
Babon JJ, et al. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462(1):1ā13.
Welsch K, et al. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017;47(7):1096ā107.
Igarashi K, et al. Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. J Biol Chem. 1994;269(20):14333ā6.
Zhou YJ, et al. Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation. Mol Cell Biol. 2000;20(12):4371ā80.
Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736ā44.
Works MG, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. J Immunol. 2014;193(7):3278ā87.
Nicolas CS, et al. The role of JAK-STAT signaling within the CNS. JAKSTAT. 2013;2(1):e22925.
Notarangelo LD, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum Mutat. 2001;18(4):255ā63.
Kreins AY, et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med. 2015;212(10):1641ā62.
Sonbol MB, et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol. 2013;4(1):15ā35.
Papp KA, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266ā76.
A study comparing Upadacitinib (ABT-494) to placebo in participants with active psoriatic arthritis who have a history of inadequate response to at least one biologic disease modifying anti-rheumatic drug (SELECTāPsA 2) (NCT03104374). https://clinicaltrials.gov/ct2/show/NCT03104374. Updated April 30, 2019. Accessed June 25 2019.
A study comparing Upadacitinib (ABT-494) to placebo in participants with active psoriatic arthritis who have an inadequate response to at least one non-biologic disease modifying anti-rheumatic drug (SELECTāPsA 1) (NCT03104400). https://clinicaltrials.gov/ct2/show/NCT03104400. Updated June 28, 2019. Accessed June 25 2019.
Mease P, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2367ā77.
An open-label, long-term extension study with filgotinib in active psoriatic arthritis (NCT03320876). https://clinicaltrials.gov/ct2/show/NCT03320876. Updated April 16, 2019. Accessed June 25 2019.
Papp K, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173(3):767ā76.
Papp K, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313ā21.
An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis (POETYK-PSO-1) (NCT03624127). https://clinicaltrials.gov/ct2/show/NCT03624127. Updated June 24, 2019. Accessed June 25 2019.
An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate-to-severe plaque psoriasis (POETYK-PSO-2) (NCT03611751). https://clinicaltrials.gov/ct2/show/NCT03611751. Updated July 1, 2019. Accessed July 1 2019.
Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.
Schafer PH, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cell Signal. 2016;28(7):753ā63.
Perez-Aso M, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015;17:249.
Schafer PH, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;2015:906349.
LEO 32731 for the treatment of moderate to severe psoriasis vulgaris (NCT02888236). https://clinicaltrials.gov/ct2/show/NCT02888236. Updated August 28, 2017. Accessed June 25 2019.
Castro G, et al. RORgammat and RORalpha signature genes in human Th17 cells. PLoS One. 2017;12(8):e0181868.
Xue X, et al. Pharmacologic modulation of RORgammat translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis. Sci Rep. 2016;6:37977.
An ascending multiple dose study with VTP-43742 in healthy volunteers (NCT03724292). https://clinicaltrials.gov/ct2/show/NCT03724292. Updated October 30, 2018. Accessed June 25 2019.
An ascending multiple dose study with VTP-43742 in healthy volunteers and psoriatic patients (NCT02555709). https://clinicaltrials.gov/ct2/show/NCT02555709. Updated October 30, 2018. Accessed June 25 2019.
McGeehan GM, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742, a RORĪ³t inhibitor, in normal healthy volunteers. J Immunol. 2016;196(1 Suppl):71.4.
Mrowietz U, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018;32(Suppl 3):3ā14.
Bruck J, et al. A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. Exp Dermatol. 2018;27(6):611ā24.
Pivotal efficacy and safety registration trial of FP187 in moderate to severe plaque psoriasis (NCT01230138). https://clinicaltrials.gov/ct2/show/NCT01230138. Updated December 11, 2012. Accessed June 25 2019.
A study to assess the efficacy and safety of XP23829 in subjects with moderate-to-severe chronic plaque-type psoriasis (NCT02173301). https://clinicaltrials.gov/ct2/show/NCT02173301. Updated March 5, 2019. Accessed June 25 2019.
Mrowietz U, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm((R))- and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017;176(3):615ā23.
Park SJ, Im DS. Sphingosine 1-phosphate receptor modulators and drug discovery. Biomol Ther (Seoul). 2017;25(1):80ā90.
Stepanovska B, Huwiler A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacol Res. 2020;154:104170.
Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91ā101.
Ohtani R, et al. Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. Mult Scler J Exp Transl Clin. 2018;4(1):2055217318759692.
ACT-128800 in patients with moderate to severe chronic plaque psoriasis (NCT01208090). https://clinicaltrials.gov/ct2/show/NCT01208090. Updated January 24, 2013. Accessed June 25 2019.
DāAmbrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis. 2016;7(1):18ā33.
Dose-finding study of MT-1303 in subjects with moderate to severe chronic plaque psoriasis (NCT01987843). https://clinicaltrials.gov/ct2/show/NCT01987843. Updated December 18, 2014. Accessed June 25 2019.
Douglas SD, Leeman SE. Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci. 2011;1217:83ā95.
Spitsin S, Pappa V, Douglas SD. Truncation of neurokinin-1 receptor-negative regulation of substance P signaling. J Leukoc Biol. 2018;103:1043ā51.
Mashaghi A, et al. Neuropeptide substance P and the immune response. Cell Mol Life Sci. 2016;73(22):4249ā64.
Aziz F. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting. Ann Palliat Med. 2012;1(2):130ā6.
Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645ā53.
Study of the efficacy, safety and tolerability of Serlopitant for the treatment of pruritus (itch) with plaque psoriasis (NCT03343639). Updated June 27, 2019. Accessed July 1 2019.
Study of the long term safety of serlopitant for the treatment of pruritus (itch) (NCT03540160). https://clinicaltrials.gov/ct2/show/NCT03540160. Updated June 19, 2019. Accessed July 1 2019.
Borea PA, et al. The A3 adenosine receptor: history and perspectives. Pharmacol Rev. 2015;67(1):74ā102.
Jacobson KA, et al. A3 adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy. Med Res Rev. 2018;38(4):1031ā72.
Fishman P, et al. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. 2012;17(7ā8):359ā66.
David M, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol. 2012;26(3):361ā7.
Trial of CF101 to treat patients with psoriasis (NCT01265667). https://clinicaltrials.gov/ct2/show/NCT01265667. Updated September 20, 2017. Accessed June 25 2019.
CF101 therapy in patients with moderate-to-severe plaque psoriasis (NCT03168256). https://clinicaltrials.gov/ct2/show/NCT03168256. Updated June 10, 2019. Accessed June 25 2019.
Zampeli E, Tiligada E. The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol. 2009;157(1):24ā33.
Gutzmer R, et al. The histamine H4 receptor is functionally expressed on T(H)2 cells. J Allergy Clin Immunol. 2009;123(3):619ā25.
Han SH, et al. Preliminary study of histamine H4 receptor expressed on human CD4(+) T cells and its immunomodulatory potency in the IL-17 pathway of psoriasis. J Dermatol Sci. 2017;88(1):29ā35.
Mommert S, et al. Human memory Th17 cells express a functional histamine H4 receptor. Am J Pathol. 2012;180(1):177ā85.
A study to determine the efficacy of ZPL-3893787 in subjects with plaque psoriasis (NCT02618616). https://clinicaltrials.gov/ct2/show/NCT02618616. Updated January 23, 2018. Accessed June 252019.
Danis J, et al. PRINS non-coding RNA regulates nucleic acid-induced innate immune responses of human keratinocytes. Front Immunol. 2017;8:1053.
Efficacy and safety of Prurisol administered orally for active mild to moderate chronic plaque psoriasis (NCT02494479). https://clinicaltrials.gov/ct2/show/NCT02494479. Updated July 19, 2017. Accessed June 25 2019.
Efficacy and safety of Prurisol administered orally for active moderate to severe chronic plaque psoriasis (NCT02949388). https://clinicaltrials.gov/ct2/show/NCT02949388. Updated February 13, 2018. Accessed June 25 2019.
Yi YS, et al. Functional roles of Syk in macrophage-mediated inflammatory responses. Mediat Inflamm. 2014;2014:270302.
Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387ā402.
Tasher D, Dalal I. The genetic basis of severe combined immunodeficiency and its variants. Appl Clin Genet. 2012;5:67ā80.
Scott DL. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis. Drugs. 2011;71(9):1121ā32.
Alzahrani KS, et al. Inhibition of spleen tyrosine kinase attenuates psoriasis-like inflammation in mice through blockade of dendritic cell-Th17 inflammation axis. Biomed Pharmacother. 2019;111:347ā58.
Platt AM, et al. The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4(+) T cell-priming capacity of dendritic cells. Rheumatology (Oxford). 2015;54(1):169ā77.
Deng GM, Kyttaris VC, Tsokos GC. Targeting Syk in autoimmune rheumatic diseases. Front Immunol. 2016;7:78.
Liu D, Mamorska-Dyga A. Syk inhibitors in clinical development for hematological malignancies. J Hematol Oncol. 2017;10(1):145.
Newland A, et al. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9ā25.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Grand, D., Navrazhina, K., Frew, J.W., Hawkes, J.E. (2021). Research Pipeline I: Oral Therapeutics for Psoriasis. In: Weinberg, J.M., Lebwohl, M. (eds) Advances in Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-030-54859-9_23
Download citation
DOI: https://doi.org/10.1007/978-3-030-54859-9_23
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-54858-2
Online ISBN: 978-3-030-54859-9
eBook Packages: MedicineMedicine (R0)